The DOI matches its Crossref record.
Clinical and molecular stratification of disease risk in medulloblastoma
Open accessAbstract
The accurate assessment of disease risk among children with medulloblastoma remains a major challenge to the field of paediatric neuro-oncology. In the current study we investigated the capacity of molecular abnormalities to increase the accuracy of disease risk stratification above that afforded by clinical staging alone. 41 primary medulloblastoma tumour samples were analysed for ErbB2 receptor expression using immunohistochemistry, and for aberrations of chromosome 17 and amplification of the MYC oncogene using fluorescence in situ hybridisation. The ErbB2 receptor and deletion of 17p were detected in 80% and 49% of tumours, respectively. 17p loss occurred either in isolation (20%), or in association with gain of 17q (29%), compatible with an isochromosome of 17q. Amplification of MYC was detected in only 2 tumours. Significant prognostic factors included, 'metastatic disease' (P = 0.0006), 'sub-total tumour resection' (P = 0.007), 'high ErbB2 receptor expression' (P = 0.003) and 'isolated 17p loss' (P = 0.003). Combined analysis of clinical and molecular factors enabled greater resolution of disease risk than clinical factors alone, identifying a sub-population of patients with particularly favourable disease outcome. These data support the hypothesis that a combination of clinical and molecular factors may afford a more reliable means of assigning disease risk in patients with medulloblastoma, thereby providing a more accurate basis for targeting therapy in children with this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Medulloblastoma Comprises Four Distinct Molecular Variants
Northcott, P. A., Korshunov, A., Witt, H., Hielscher, T., Eberhart, C. G., Mack, S., Bouffet, E., Clifford, S. C., Hawkins, C. E., French, P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4324 · Cited by 1,339
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma
Huse, J. T., & Holland, E. C. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2818 · Cited by 763
Kool, M., Koster, J., Bunt, J., Hasselt, N. E., Lakeman, A., van Sluis, P., Troost, D., Meeteren, N. S.-V., Caron, H. N., Cloos, J., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003088 · Cited by 722
Self-citationCytogenetic Prognostication Within Medulloblastoma Subgroups
Shih, D. J. H., Northcott, P. A., Remke, M., Korshunov, A., Ramaswamy, V., Kool, M., Luu, B., Yao, Y., Wang, X., Dubuc, A. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9539 · Cited by 313
Ellison, D. W., Kocak, M., Dalton, J., Megahed, H., Lusher, M. E., Ryan, S. L., Zhao, W., Nicholson, S. L., Taylor, R. E., Bailey, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.2810 · Cited by 302
Self-citation
Metadata
- Authors
- Gilbertson, R., Wickramasinghe, C., Hernan, R., Balaji, V, Hunt, D., Jones-Wallace, D., Crolla, J., Perry, R., Lunec, J., Pearson, A., & Ellison, D.
- Venue
- British Journal of Cancer
- Published
- 2001-08
- Volume
- 85
- Issue
- 5
- Pages
- 705-712
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2001140923
- Cited by
- 168
- References
- 0
- FWCI
- 5.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical and molecular stratification of disease risk in medulloblastoma. https://app.cochat.ai/papers/10.1054/bjoc.2001.1987
- The paper
- Gilbertson, R., Wickramasinghe, C., Hernan, R., Balaji, V, Hunt, D., Jones-Wallace, D., Crolla, J., Perry, R., Lunec, J., Pearson, A., & Ellison, D. (2001). Clinical and molecular stratification of disease risk in medulloblastoma. British Journal of Cancer. https://doi.org/10.1054/bjoc.2001.1987
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.